[News] Larotrectinib in TRK fusion-positive cancers
The TRK inhibitor larotrectinib is associated with a high proportion of patients achieving an overall response with TRK fusion-positive cancers, according to a new combined analysis of three trials.
Source: The Lancet Oncology - Category: Cancer & Oncology Authors: Talha Khan Burki Tags: News Source Type: research
More News: Cancer | Cancer & Oncology